title: Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy.
abstract: Children who require long-term glucocorticoid treatment often demonstrate poor growth. Growth hormone (GH) secretion is decreased during glucocorticoid treatment, and this decrease may be due to a relative excess of the hypothalamic hormone somatostatin (SRIF). GH-releasing peptide-2 (GHRP-2) is a GH secretagogue that acts via multiple mechanisms at multiple sites. One of its proposed mechanisms is the ability to bypass SRIF blockade of GH secretion. We measured the ability of GHRP-2 to release GH before and during prednisone therapy (20 mg orally three times daily for 4 days). The degree of preservation of GH secretion and the pattern of GH release in response to GHRP-2 were compared with those observed in response to arginine, a known SRIF inhibitor. GH release in response to GHRP-2 and arginine was measured in the same eight subjects before and during prednisone therapy. Before prednisone, peak GH levels in response to arginine and GHRP-2 were 8.8 +/- 2.8 and 80.8 +/- 21.2 microg/L. During prednisone therapy, the peak GH level in response to arginine and to GHRP-2 was 20.1 +/- 8.3 and 71.3 +/- 18.4 microg/L, respectively. The difference in peak values before and after prednisone was not significant. The time to the peak GH level during prednisone therapy occurred sooner for both arginine and GHRP-2. The pattern of GH release to arginine and to GHRP-2 was not identical, and the mean area under the curve for GH release to GHRP-2 decreased significantly with steroid treatment (P = .04), suggesting that GHRP-2 acts by mechanisms additional to the removal of SRIF inhibition. GHRP-2 elicited a 10-fold greater GH response than arginine at baseline, and the GH response was threefold greater versus arginine even in the face of prednisone therapy. GH release occurred earlier for both arginine and GHRP-2 during steroid treatment. We propose that this may suggest an increased storage phenomenon due to the blockade of GH secretion by glucocorticoids and then a sudden release with SRIF inhibition. If GHRP-2 can indeed counteract the inhibitory effect of glucocorticoids on GH secretion, then a new form of therapy may be available to support growth in children who must receive long-term steroid treatment.
authors.affiliation: Department of Pediatrics, Emory University, Atlanta, GA, USA.
authors.forename: L R
authors.initials: LR
authors.lastname: Meacham
authors.forename: F L
authors.initials: FL
authors.lastname: Culler
authors.forename: H
authors.initials: H
authors.lastname: Abdul-Latif
authors.forename: K M
authors.initials: KM
authors.lastname: Sullivan
authors.forename: C Y
authors.initials: CY
authors.lastname: Bowers
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001120:Arginine / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000378:metabolism*; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology*; D013004:Somatostatin / Q000037:antagonists & inhibitors; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D009842:Oligopeptides; D019382:Human Growth Hormone; D013004:Somatostatin; D001120:Arginine; C091874:growth hormone-releasing peptide-2; D011241:Prednisone